Mologic and Alamar team up to fight future threats from Covid

Mologic in Bedford UK and Maine in the US and Alamar Biosciences in California are partnering on the project.

The collaboration will utilise Alamar’s novel antibodies against SARS-CoV-2 Nucleocapsid (N) protein for Mologic’s future COVID-19 RDTs.

Easy-to-use and cost-effective RDTs are a key tool for controlling the spread of COVID-19, including in low resource settings. Mologic has already launched COVID-19 antigen tests (COVIOS and COVIGO for personal self-testing) based on its lateral flow assay technology, utilising high affinity, paired antibodies specific for the SARS-CoV-2 nucleoprotein antigen.  Read more

Related Posts

Portland startup Marin Skincare launches lobster-based lip treatment

Portland startup Marin Skincare, known for its “lobster lotion,” is expanding that product line to include lip treatments.  Founded out of the University...

20 November 2023

UMaine scientists use eDNA to enhance river herring recovery research in Penobscot River

University of Maine researchers are seeking to gain more insight into river herring recovery in the Penobscot River using a novel...

16 November 2023

FocusMaine co-founder named group’s next president

Nearly a decade after Andrea Cianchette Maker joined forces with Michael Dubyak to launch FocusMaine, Maker will lead the organization as...

15 November 2023